mAbxience, a company specialized in the research, development, manufacturing and global commercialization of monoclonal antibody biosimilars, part of the Insud Pharma Group, and Amneal Pharmaceuticals, an integrated specialty pharmaceutical company powered by a robust U.S. generics business, have signed an exclusive licensing and supply agreement in the U.S. for mAbxience’s bevacizumab, a biosimilar candidate for Avastin. Under the milestone based commercial agreement mAbxience will lea...